| Assessment Status | Rapid Review Complete |
| HTA ID | 23058 |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | Pembrolizumab as monotherapy for the treatment of mismatch repair deficient or microsatellite instability-high tumours in adults with unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. |
| Assessment Process | |
| Rapid review commissioned | 20/09/2023 |
| Rapid review completed | 25/10/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care. |
| Full HTA commissioned by the HSE | 01/11/2023 |
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.